CVRx (CVRX) Projected to Post Quarterly Earnings on Monday

CVRx (NASDAQ:CVRX) is projected to issue its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect CVRx to post earnings of ($0.5043) per share and revenue of $14.49 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:30 PM ET.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). The firm had revenue of $16.02 million for the quarter, compared to analyst estimates of $15.75 million. CVRx had a negative return on equity of 99.32% and a negative net margin of 94.10%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Performance

NASDAQ:CVRX traded down $0.20 during mid-day trading on Monday, hitting $7.78. 53,745 shares of the stock were exchanged, compared to its average volume of 331,838. The stock has a market capitalization of $205.49 million, a price-to-earnings ratio of -3.79 and a beta of 0.90. The firm’s 50-day simple moving average is $8.02 and its 200 day simple moving average is $8.10. The company has a debt-to-equity ratio of 1.26, a quick ratio of 6.72 and a current ratio of 7.63. CVRx has a fifty-two week low of $4.30 and a fifty-two week high of $11.30.

Insider Buying and Selling

In related news, Director Mudit K. Jain bought 46,800 shares of the business’s stock in a transaction on Friday, February 20th. The shares were purchased at an average cost of $6.36 per share, with a total value of $297,648.00. Following the acquisition, the director owned 980,183 shares of the company’s stock, valued at $6,233,963.88. This represents a 5.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 18.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of CVRx by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,090,226 shares of the company’s stock valued at $8,798,000 after purchasing an additional 12,948 shares during the period. GSK plc bought a new stake in CVRx in the 4th quarter valued at about $7,154,000. Balyasny Asset Management L.P. increased its position in CVRx by 17.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 814,943 shares of the company’s stock valued at $5,786,000 after buying an additional 118,683 shares in the last quarter. Geode Capital Management LLC increased its position in CVRx by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company’s stock valued at $2,249,000 after buying an additional 23,079 shares in the last quarter. Finally, Marshall Wace LLP increased its position in CVRx by 238.1% in the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock valued at $2,058,000 after buying an additional 246,548 shares in the last quarter. 75.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CVRX has been the topic of a number of recent research reports. Cantor Fitzgerald upgraded CVRx to a “strong-buy” rating in a research note on Tuesday, February 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price target on shares of CVRx in a research note on Tuesday, April 14th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.50.

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.